Literature DB >> 20351345

Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study.

Krishna Gaddam1, Cecilia Corros, Eduardo Pimenta, Mustafa Ahmed, Thomas Denney, Inmaculada Aban, Seidu Inusah, Himanshu Gupta, Steven G Lloyd, Suzanne Oparil, Ahsan Husain, Louis J Dell'Italia, David A Calhoun.   

Abstract

We have shown previously that patients with resistant hypertension and hyperaldosteronism have increased brain natriuretic peptide suggestive of increased intravascular volume. In the present study, we tested the hypothesis that hyperaldosteronism contributes to cardiac volume overload. Thirty-seven resistant hypertensive patients with hyperaldosteronism (urinary aldosterone > or = 12 microg/24 hours and plasma renin activity < or = 1.0 ng/mL per hour) and 71 patients with normal aldosterone status were studied. Both groups had similar blood pressure and left ventricular mass, whereas left and right ventricular end-diastolic volumes measured by cardiac MRI were greater in high versus normal aldosterone subjects (P<0.05). Spironolactone treatment (19 patients in the high aldosterone group and 15 patients from the normal aldosterone group participated in the follow-up) resulted in a significant decrease in clinic systolic blood pressure, right and left ventricular end diastolic volumes, left atrial volume, left ventricular mass, and brain natriuretic peptide at 3 and 6 months of follow-up in patients with high aldosterone, whereas in those with normal aldosterone status, spironolactone decreased blood pressure and left ventricular mass without changes in ventricular or atrial volumes or plasma brain natriuretic peptide. Hyperaldosteronism causes intracardiac volume overload in patients with resistant hypertension in spite of conventional thiazide diuretic use. Mineralocorticoid receptor blockade induces rapid regression of left ventricular hypertrophy irrespective of aldosterone status. In subjects with high aldosterone, mineralocorticoid receptor blockade induces a prominent diuretic effect compared with a greater vasodilatory effect in subjects with normal aldosterone status.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20351345      PMCID: PMC2864599          DOI: 10.1161/HYPERTENSIONAHA.109.141531

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  41 in total

1.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology.

Authors:  Roberto M Lang; Michelle Bierig; Richard B Devereux; Frank A Flachskampf; Elyse Foster; Patricia A Pellikka; Michael H Picard; Mary J Roman; James Seward; Jack S Shanewise; Scott D Solomon; Kirk T Spencer; Martin St John Sutton; William J Stewart
Journal:  J Am Soc Echocardiogr       Date:  2005-12       Impact factor: 5.251

2.  Impact of aldosterone on left ventricular structure and function in young normotensive and mildly hypertensive subjects.

Authors:  M P Schlaich; H P Schobel; K Hilgers; R E Schmieder
Journal:  Am J Cardiol       Date:  2000-05-15       Impact factor: 2.778

3.  Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I.

Authors:  Michael Stowasser; James Sharman; Rodel Leano; Richard D Gordon; Gregory Ward; Diane Cowley; Thomas H Marwick
Journal:  J Clin Endocrinol Metab       Date:  2005-06-07       Impact factor: 5.958

4.  Low-renin status in therapy-resistant hypertension: a clue to efficient treatment.

Authors:  Ivar K Eide; Peter A Torjesen; Anders Drolsum; Almira Babovic; Nils P Lilledahl
Journal:  J Hypertens       Date:  2004-11       Impact factor: 4.844

5.  Mineralocorticoids, hypertension, and cardiac fibrosis.

Authors:  M Young; M Fullerton; R Dilley; J Funder
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

6.  Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism.

Authors:  Mari K Nishizaka; M Amin Zaman; Sharon A Green; Kerry Y Renfroe; David A Calhoun
Journal:  Circulation       Date:  2004-06-01       Impact factor: 29.690

7.  Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study.

Authors:  S M Vaziri; M G Larson; E J Benjamin; D Levy
Journal:  Circulation       Date:  1994-02       Impact factor: 29.690

8.  Serum aldosterone and the incidence of hypertension in nonhypertensive persons.

Authors:  Ramachandran S Vasan; Jane C Evans; Martin G Larson; Peter W F Wilson; James B Meigs; Nader Rifai; Emelia J Benjamin; Daniel Levy
Journal:  N Engl J Med       Date:  2004-07-01       Impact factor: 91.245

9.  Role of aldosterone in left ventricular hypertrophy in hypertension.

Authors:  Kiyoshi Matsumura; Koji Fujii; Hideyuki Oniki; Masayo Oka; Mitsuo Iida
Journal:  Am J Hypertens       Date:  2006-01       Impact factor: 2.689

10.  Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension.

Authors:  C G Brilla; L S Matsubara; K T Weber
Journal:  Am J Cardiol       Date:  1993-01-21       Impact factor: 2.778

View more
  50 in total

1.  Cardiac dimensions are largely determined by dietary salt in patients with primary aldosteronism: results of a case-control study.

Authors:  Eduardo Pimenta; Richard D Gordon; Ashraf H Ahmed; Diane Cowley; Rodel Leano; Thomas H Marwick; Michael Stowasser
Journal:  J Clin Endocrinol Metab       Date:  2011-06-01       Impact factor: 5.958

Review 2.  Arterial Hypertension, Atrial Fibrillation, and Hyperaldosteronism: The Triple Trouble.

Authors:  Teresa M Seccia; Brasilina Caroccia; Gail K Adler; Giuseppe Maiolino; Maurizio Cesari; Gian Paolo Rossi
Journal:  Hypertension       Date:  2017-04       Impact factor: 10.190

3.  Alterations in vascular function in primary aldosteronism: a cardiovascular magnetic resonance imaging study.

Authors:  P B Mark; S Boyle; L U Zimmerli; E P McQuarrie; C Delles; E M Freel
Journal:  J Hum Hypertens       Date:  2013-07-25       Impact factor: 3.012

4.  Effect of spironolactone on diastolic function in hypertensive left ventricular hypertrophy.

Authors:  A Gupta; C G Schiros; K K Gaddam; I Aban; T S Denney; S G Lloyd; S Oparil; L J Dell'Italia; D A Calhoun; H Gupta
Journal:  J Hum Hypertens       Date:  2014-09-18       Impact factor: 3.012

Review 5.  Preferred Fourth-Line Pharmacotherapy for Resistant Hypertension: Are We There Yet?

Authors:  Hamish Cg Prosser; Cynthia Gregory; Dagmara Hering; Graham S Hillis; Greg Perry; Johan Rosman; Carl Schultz; Mark Thomas; Gerald F Watts; Markus P Schlaich
Journal:  Curr Hypertens Rep       Date:  2017-04       Impact factor: 5.369

6.  Left ventricular torsion shear angle volume analysis in patients with hypertension: a global approach for LV diastolic function.

Authors:  Chun G Schiros; Ravi V Desai; Bharath Ambale Venkatesh; Krishna K Gaddam; Shilpi Agarwal; Steven G Lloyd; David A Calhoun; Thomas S Denney; Louis J Dell'italia; Himanshu Gupta
Journal:  J Cardiovasc Magn Reson       Date:  2014-09-26       Impact factor: 5.364

Review 7.  Drug therapy of apparent treatment-resistant hypertension: focus on mineralocorticoid receptor antagonists.

Authors:  Daniel Glicklich; William H Frishman
Journal:  Drugs       Date:  2015-04       Impact factor: 9.546

8.  Global- and renal-specific sympathoinhibition in aldosterone hypertension.

Authors:  Thomas E Lohmeier; Boshen Liu; Drew A Hildebrandt; Adam W Cates; Dimitrios Georgakopoulos; Eric D Irwin
Journal:  Hypertension       Date:  2015-04-20       Impact factor: 10.190

9.  Body Mass Index Predicts 24-Hour Urinary Aldosterone Levels in Patients With Resistant Hypertension.

Authors:  Tanja Dudenbostel; Lama Ghazi; Mingchun Liu; Peng Li; Suzanne Oparil; David A Calhoun
Journal:  Hypertension       Date:  2016-08-15       Impact factor: 10.190

Review 10.  How can resistant hypertension be identified and prevented?

Authors:  Anna Solini; Luis M Ruilope
Journal:  Nat Rev Cardiol       Date:  2013-03-05       Impact factor: 32.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.